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Abstract
Human papillomaviruses (HPV) have genotype-specific disease associations, with high-risk
alpha types causing at least 5% of all human cancers. Despite these conspicuous differ-
ences, our data show that high- and low- risk HPV types use similar approaches for genome
maintenance and persistence. During the maintenance phase, viral episomes and the host
cell genome are replicated synchronously, and for both the high- and low-risk HPV types,
the E1 viral helicase is non-essential. During virus genome amplification, replication
switches from an E1-independent to an E1-dependent mode, which can uncouple viral DNA
replication from that of the host cell. It appears that the viral E2 protein, but not E6 and E7, is
required for the synchronous maintenance-replication of both the high and the low-risk HPV
types. Interestingly, the ability of the high-risk E6 protein to mediate the proteosomal degra-
dation of p53 and to inhibit keratinocyte differentiation, was also seen with low-risk HPV E6,
but in this case was regulated by cell density and the level of viral gene expression. This
allows low-risk E6 to support genome amplification, while limiting the extent of E6-mediated
cell proliferation during synchronous genome maintenance. Both high and low-risk E7s
could facilitate cell cycle re-entry in differentiating cells and support E1-dependent replica-
tion. Despite the well-established differences in the viral pathogenesis and cancer risk, it
appears that low- and high-risk HPV types use fundamentally similar molecular strategies to
maintain their genomes, albeit with important differences in their regulatory control. Our
results provide new insights into the regulation of high and low-risk HPV genome replication
and persistence in the epithelial basal and parabasal cells layers. Understanding the mini-
mum requirement for viral genome persistence will facilitate the development of therapeutic
strategies for clearance.
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Author summary
Human papillomavirus research has been prioritised towards understanding the progres-
sion of high-risk HPV infections to malignant cancer, rather than the regulation of the
HPV productive cycle. Low-risk HPV types are often considered as a ‘less effective’ ver-
sion of their high-risk counterparts. To date, they have been inadequately investigated and
have generally served as reference viruses that lack oncogenic HPV functions. Here we
carried out a comparative analysis using the most prominent high-risk (HPV16) and low-
risk (HPV11) HPV papillomaviruses, focusing on viral genome replication and mainte-
nance in the epithelial basal layer. During the maintenance phase, the E1 viral helicase of
both HPV types are dispensable. Neither E6 nor E7 proteins are required for the mainte-
nance replication. Once cells become confluent, replication switches from an E1-indepen-
dent to an E1-dependent mode and requires p53 degradation by E6. Interestingly, the
characteristic ability of high-risk E6 to degrade p53 and inhibit keratinocyte differentia-
tion was also seen with low-risk HPV E6, but in this case was regulated by cell density and
the extent of viral gene expression. Despite the differences in the pathogenicity of low-
and high-risk HPV types, they appear to follow similar molecular strategies to complete
viral life cycle.
Introduction
Papillomaviruses (PV) are small double-stranded DNA viruses which infect stratified epithelia,
with the completion of their life cycle being intimately linked to the terminal differentiation
program of keratinocytes. One of the most distinctive characteristics of papillomaviruses is
their genotype-specific host-restriction, and the preference shown by different papillomavirus
types for distinct anatomical sites[1–3]. Human papillomaviruses (HPVs), which consist of
more than 200 HPV types, are subdivided into 5 genera, and within the alpha genus, HPVs are
further divided into low- and high-risk types based on the cancer risk associated with their
infection [4, 5].
HPVs express a relatively small number of early and late viral genes during their life cycle,
which are tightly regulated according to the differentiation stage of the infected keratinocytes.
The viral genes may be categorized as ‘core genes’ or ‘accessory genes’. All known papillomavi-
ruses have evolved a group of core genes that were present early during papillomavirus specia-
tion, which share similarities in sequence and protein function. The core genes play primary
roles in viral genome replication and amplification (E1 and E2) as well as virion assembly (L1
and L2) [6–10]. In contrast, the accessory genes (E6, E7 and E5), which are often referred to as
viral oncogenes, have evolved in each papillomavirus type as it adapted to different epithelial
niches [11–13]. The sequence and function of these genes are similar yet divergent between
types compared to the core genes. In general, accessory genes are involved in modifying the
cellular environment in order to complete the viral life cycle at the site of infection. Accessory
genes play a variety of important functions at different stages of the viral life cycle, such as the
maintenance of infection in the basal layer and the amplification of viral genomes in the supra-
basal layers. As such, the function of these accessory genes as well as their regulation may
largely attribute to virus diversity in tropism and pathogenicity [5, 6]. In fact, the deregulation
of the accessory genes of high-risk HPV can mediate the progression to invasive cancer [4, 14].
The high-risk HPV-mediated carcinogenic process has drawn most of the research effort in
the past decades, leaving open important questions about the comparative analysis of the evo-
lutionary adaptation of different HPV types in relation to their specific epithelial sites of
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infection. Among the best characterized functions of high-risk HPVs there are the E6-medi-
ated degradation of p53 and PDZ domain-containing proteins and the activation of hTERT
(reviewed in [12]). High-risk HPV E7 is known to interact and destabilise pRB family proteins,
promoting cell cycle re-entry in the parabasal layers of the epithelium and above (reviewed in
[11]). Furthermore, both E6 and E7 expressed by high-risk HPV types have multiple additional
functions, such as the inhibition of differentiation, apoptosis and host-immune response. In
many cases, low-risk HPV E6 and E7 are considered as a ‘de-potentiated’ version of their high-
risk counterparts. These HPV types are maintained and propagated in the general population
without having the carcinogenic properties of high-risk HPVs, indicating that the induction of
cancer is a collateral effect of the life cycle strategy of high-risk HPVs rather than an
adaptation.
In this study, we have performed a comparative analysis of how ‘core’ and ‘accessory’ pro-
teins cooperate in promoting the replication of both low- and high-risk viral episomes. We
have used HPV11 and 16 as the key prototypes of low- and high-risk alpha HPV types respec-
tively, and used the immortal and isogenic NIKS keratinocyte cell line as a cell model to draw
direct comparisons of the life cycle strategies used by the two viruses. We have identified a
two-phase HPV replication mode common to both low- and high-risk alpha papillomaviruses
that is regulated by cell density. Our data shows that viral replication switches from requiring
E2 and being E1-independent while genomes are maintained, to being E1-dependent as kerati-
nocytes commit to differentiation at high cell density, a situation that also requires the function
of E6 and E7. Curiously, the low-risk E6 protein was necessary in order to sustain low-risk
HPV genome copy number as cell confluence was reached, and that like high-risk E6, this was
dependent on E6-mediated p53 proteasomal degradation. Our results suggest that for both
high and low-risk HPVs, that E1 is non-essential for synchronous HPV genome replication
during maintenance, and that the low-risk E6 protein has a p53-degradation function that is
regulated at cell confluence, and which like that high-risk HPV types, can inhibit commitment
to differentiation and stimulate cell cycle entry.
Materials and methods
Cell culture
293T (ATCC) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, SIGMA)
supplemented with 10% fetal calf serum (FCS, HyClone) and 1% penicillin and streptomycin.
NIKS (a gift from Paul Lambert, McArdle Laboratory for Cancer Research, University of Wis-
consin), a HPV-negative spontaneously immortalised human keratinocyte cell line, was main-
tained at sub-confluence on γ-Irradiated J2 3T3 feeder cells (a gift from Paul Lambert) in F
medium with all supplements as previously described [15]. Bromodeoxyuridine (BrdU) was
used at a final concentration of 30 μg/ml for 18 hours.
Plasmid construction and site-directed mutagenesis
The pSPW12 plasmid was a kind gift from Prof. Margaret Stanley (University of Cambridge)
containing the HPV16 genome. The pBT-1 clone of HPV11 (Hershey) plasmid was a kind gift
from Prof. Neil Christensen (The Pennsylvania State University). HPV16E6SAT, HPV16Δ
PBM, HPV16 E1 defective mutant were described previously [16, 17]. All mutant genomes
were constructed using a KOD -Plus- Mutagenesis Kit (TOYOBO), prior to DNA sequencing
to ensure that no additional base changes were present. The mutants that were constructed in
this study comprise the HPV16 E1 helicase defective mutant (K383 to A), HPV16 E6 defective
mutant (D9 to STOP), HPV16 E7 defective mutant (L13 to STOP), HPV16 E2 defective
mutant (G50 to stop), HPV11E1 defective mutant (D46 to STOP and M47 to STOP), HPV11
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E1 helicase defective mutant (K384 to A), HPV11 E6 defective mutant (E2 to STOP), HPV11
E7 defective mutant (L15 to STOP) and the HPV11 E2 defective mutant (L79 to STOP). The
primer sequences used for mutagenesis are available upon request.
In order to construct HPV11 and HPV16 reporter genomes, two restriction enzyme recog-
nition sites, BglII and XhoI, were generated in pSPW12 (HPV16), pBT-1 (HPV11) and pSE-
LECT–zeo-GFPBsr (InvivoGen) using the KOD -Plus- Mutagenesis system (Fig 2A, primer
sequences available upon request). All mutants were sequenced to ensure that no additional
Fig 1. Difference between low and high-risk HPV types. (A) The viral genome copy number per cell was measured by qPCR, using the cellular GAPDH
gene to estimate cell number. All DNA samples were digested with DpnI to eliminate residual input DNA. The viral genome copy number per cell at
passage 2 was set at 100%, and subsequent change in copy number normalized to this. HPV16 genome, but not HPV11, was well maintained until passage
8. The average viral genome copy number per cell at passage 2 is shown with standard deviation (SD). (B) NIKS or NIKS harboring HPV11 or HPV16 at
days 3 and 7 were stained with K10 (red), to identify the early stage of differentiation; MCM (red), to identify the G1 and S phase compartments, and DAPI
(blue) as a nuclear counterstain. Bar = 200μm. (C) Proportion of MCM positive cells at each time point is counted and shown. (D) NIKS, or NIKS
harbouring HPV11 or HPV16 were counted in triplicate at days 1, 3, 5, 7 and 9 post-seeding. The cells were pre-confluent at day 3, confluent at day5 and
post confluent at days7 and 9. (E) NIKS transfected with HPV11 (left) or HPV16 (right) were seeded at day 0, and collected at days 1, 2, 3 (pre-confluence),
day 4 (confluence) and day 7 (post-confluence). The viral genome copy number per cell was measured as outlined in Fig 1A above. All DNA samples were
digested with DpnI to remove residual input DNA. The viral genome copy number per cell at each day 1 timepoint, was set at 100%. N.S. = no significant
difference compared with each other. The single asterisk indicates P values of<0.01.
https://doi.org/10.1371/journal.ppat.1007755.g001
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Fig 2. HPV11 and HPV16 are partitioned similarly in dividing NIKS cells. (A) The position of the hEF1-HTLV promoter-driven
GFP-Blastocidin gene is shown in the context of the HPV11 and HPV16 genomes. The region between nt 5140 and 7073 is substituted by the
GFPbsr cassette in HPV11GFPbsr, with a similar substitution between 5208 and 7208 in HPV16GFPbsr. (B) NIKS/HPV11GFPbsr or NIKS/
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base changes were present. The mutated pSPW12-BglII/XhoI, pBT-1-BglII/XhoI and pSE-
LECT–zeo-GFPBsr-BglII/XhoI were excised from the BglI and XhoI sites. These two flagments,
the pSPW12- BglII/XhoI plasmid or pBT-1-BglI-XhoI and GFPBsr-BglI/XhoI, were ligated
using Ligation high Ver.2 (TOYOBO).
Generation of NIKS cell lines containing HPV genomes
Plasmids containing HPV16 and HPV11 genomes (wild type or mutant) were digested with
BamHI to release the whole viral genome. The linearized HPV11 or HPV16 genomes were
then re-circularized and purified as described previously, before being co-transfected with a
plasmid encoding blastocidin into NIKS cells [18]. 2x105 cells were seeded in each well of a
6-well plate the day before transfection with F-media incomplete (no EGF). The cells were
transfected with 1600 ng of re-circularized HPV DNA, and 400 ng of pcDNA6 encoding a
blasticidin resistance gene (Invitrogen), using FuGENE HD (Promega). The next day the cells
were seeded onto a 75 cm2 flask over blastcidin-resistant feeders with F-media incomplete,
then NIKS cells were selected with 4 μg/ml blasticidin S with F-media complete (with 10 ng/ml
of EGF) for 4 days and cultured extra 2–3 in the absence of Blastcidin and designated passage
one (P1). All experiments were carried out in triplicate using NIKS cell lines containing HPV
genomes which were generated at least two independent transfections.
Monitoring HPV genome replication
3.3x105 NIKS cells containing HPV genomes were seeded in to a 25cm2 flask with the same
number of feeder cells in F-media complete. Cells were collected for analysis at day 1, 2, 3, 4
and 7. All experiments were done using NIKS cells containing > than 10 copy per cell of each
HPV genome at passage 2 post-transfection,.
Vector construction and retroviral infection
The production and infection of recombinant retroviruses were accomplished as previously
described [19]. Construction of retrovirus vectors LXSN-HPV16E6, HPV16E6SAT, HPV16E
6ΔPDZ, HPV16E7, HPV16E6E7, HPV11E6, HPV11E7, HPVE6E7 were described previously
[20]. Retrovirus vectors of LXSN-HPV11E6, HPV11E7, and HPVE6E7 were constructed by
cloning ORF of HPV11 E6 and/or E7 into LXSN using Gateway Recombination cloning tech-
nology (Thermo Fisher Scientific) following the manufacturer’s instruction (primer sequences
available upon request). LXSN-11E6W133R was constructed using KOD -Plus- Mutagenesis
Kit (primer sequences available upon request) and sequenced to ensure that no additional
base changes was present. The E6AP-specific shRNA constructs pCL-SI-MSCVpuro-H1R-
E6APRi4 was described previously [21]. To generate NIKS cells expressing E6 and/or E7, the
cells were seeded 1 day before and inoculated with at MOI of 5 in the presence of 4 μg/ml of
Polybrene (Santa Cruz) followed by Geneticin (Thermo Fisher Scientific) selection (400 μg/
ml) for 4 days.
HPV16GFPbsr cells were cultured to pre-confluence before FACS sorting into 4 groups on the basis of GFP intensity. Average HPV genome copy
number in each group was determined by qPCR and is shown on the y-axis. (C) A uniform GFP intensity is seen in cells within NIKS/
HPV11GFPbsr and NIKS/HPV16GFPbsr colonies following expansion in tissue culture. Enlarged images of the boxed colony are also shown.
Colonies shown are representative of those analysed in (D). (D) NIKS/HPV11GFPbsr and NIKS/HPV16GFPbsr cells were plated along with
parental NIKS, and colony size allowed to increase. 4 days later, the GFP intensity of cells within 20 HPV-positive colonies was investigated. For
each individual colony, the green/red diamonds indicate mean GFP-intensity. Error bars show the extent to which GFP intensity varied in
individual cells within each colony. (E) The individual GFP intensity of each cell was normalized to the mean GFP intensity of cells in its colony.
Although individual colonies differed in their mean GFP intensity, the relative variation in GFP signal in individual cells within each colony was
similar. Not obvious differences were apparent between HPV16 and 11.
https://doi.org/10.1371/journal.ppat.1007755.g002
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siRNA transfection
For the delivery of siRNAs, 3.3x105 of cells were seeded on 25cm2 flasks and transfected 12nM
of siRNA using HiPerfect Transfection Reagent (Qiagen) at days 0 and 4. Non-targeting
siRNA (MISSION siRNA Universal Negative Control (Sigma)) was used as a negative control
and ON-TARGET plus Human TP53 (Dharmacon) was used as a siRNA to p53.
qPCR and RT-qPCR
Total DNA from NIKS for qPCR was purified using a QIAamp DNA Mini Kit (Qiagen),
according to the manufacturer’s instructions. All samples were digested with DpnI to remove
any residual input DNA prior to analysis. The RNA from NIKS for RT-qPCR was purified by
using an RNeasy Mini Kit (Qiagen), and cDNA was synthesised with SuperScript III Reverse
Transcriptase (Thermo Fisher scientific) using 100 μM random hexamer primers, according
to the manufacturer’s instructions. The HPV genome and GAPDH were measured by a ViiA 7
Real-Time PCR System (Life Technologies) using Power SYBR Green/ROX master mix
(Thermo Fisher scientific) with 15 min denaturation at 95˚C, followed by 45 cycles of 95˚C for
15s and 60˚C for 60s. The PCR primers for qPCR were as follows. The HPV11 forward primer
was 5’-ACATTAGATCCGTGGACAGTACAATC-3’ or 5’-TCGTCCAGCCTAGACATTGA
G-3’, HPV11 reverse primer was 5’-TTCCTTCTTTGGTGCTTGTTGTAA-3’ or 5’- TCCAAT
CGTATGCATTTCCA-3’, HPV16 forward primer was 5’-TGTTTCAGGACCCACAGGAGC-
3’, HPV16 reverse primer was 5’- CGCAGTAACTGTTGCTTGCAG-3’, GAPDH forward
primer was 5’-CCTCCCGCTTCGCTCTCT-3’, GAPDH reverse primer was 5’-CTGGCGACG
2CAAAAGAAGA-3’. To quantitate HPV DNA levels in HPV genome-containing cell popula-
tions and cell lines, HPV copy number per cell was expressed relative to GAPDH copy num-
ber. The human genome blast using designed primers and probe for human GAPDH
indicated that there are 4 copies, comprising 2 copies of GAPDH and 2 pseudogene copies of
GAPDH per NIKS cell. This was confirmed by determination of GAPDH copy number against
known NIKS cell number. The copy number of virus genomes per cell was found to vary at
passage 2 between experiments, with HPV11 WT and mutant genomes typically present at
around 100 copies per cell. The viral genome copy number per cell at passage 2, day 1 was set
at 100%, and subsequent changes in copy number were normalized to this. The quantification
of viral gene expression was carried out as described previously [18].
Immunofluorescence
2.4x104 cells were seeded in each well of a 4-well culture slide (Falcon) and cultured for 3 and 7
days. The cells were washed in PBS and fixed in 4% paraformaldehyde (PFA) in PBS for 30
min. at room temperature. The cells were permeabilised in PBS with 0.1% Triton X-100 (Pro-
mega) for 30 min., then washed in PBS. The cells were blocked in 10% normal goat serum
(Cell Signaling Technology) in PBS for 1 hour. The antibodies used were anti-Keratin10 anti-
body (dilution 1:200, Thermo Fisher Scientific), anti-p53 (DO-1) antibody (dilution 1:300,
Santa Cruz), anti-MCM antibody (dilution 1:100, Abcam) an anti-mouse Alexa 594-conju-
gated antibody (dilution 1:150, Thermo Fisher Scientific). For p53 and MCM, the signal was
amplified using a Tyramide Signal Amplification Kit (Perkin-Elmer), according to the manu-
facturer’s instructions. Finally, the cells were mounted in mounting medium (Agar Scientific)
for visualization. The number of cells with positive signal were quantified using ilastik
software.
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SDS-PAGE and Western blotting
Proteins were extracted from cells using RIPA buffer and quantified using the BCA protein
assay kit (Pierce), before being separated on 4–12% gradient polyacrylamide-SDS-Tris-Tricine
denaturing gel (Invitrogen) and transferred onto PVDF membranes (Bio-Rad). After transfer,
membranes were blocked for 1 hour at room temperature in 1% milk in PBS-T (PBS, 0.1%
tween20). Blots were then incubated overnight at 4˚C with the appropriate primary antibody
diluted in 1% milk PBS-T. Primary antibodies used were anti-HPV16E6 (2E-3F8, Euromedex),
anti-HPV16E7 (NM2, Santa Cruz), anti-p21 (EA10, Abcam), anti-p53 (DO-1, Santa Cruz),
anti-GAPDH (Millipore), followed by the appropriate HRP-conjugated secondary antibody
(GE Healthcare), and detection using ECL, or ECL plus kits (GE Healthcare) or by the appro-
priate IRDye 800CW fluorescent secondary antibody (Licor) followed by detection using an
Odissey imaging system (Licor).
Fluorescent activated cell sorting (FACS)
Sub-confluent NIKS were collected and fixed for 10 min. in 4% PFA in PBS at a concentration
of 1x106 cells/ml at room temperature. Immediately before sorting, the cells were passed
through a 40μm cell strainer (BD Biosciences). The cells were sorted on a Dako Cytomation
MoFlo MLS high-speed cell sorter. DNAs were extracted from the sorted cells as described
above.
p53 reporter assay
5x104 cells were seeded in each well of a 12-well and transfected Cignal p53 Pathway Reporter
Assay Kit (Qiagen) at the same day, according to the manufacturer’s instructions. The cells
were cultured for 3 or 7 days and collected. The activities of firefly and Renilla luciferases were
measured by a FLUOstar Omega Microplate Reader (BMG LABTECH) using Dual-Luciferase
Reporter Assay System (Promega), according to the manufacturer’s instructions.
Southern blot analyses
TDIG-labelled probes comprising the entire HPV11 or HPV16 genome were prepared, and
Southern blot analyses were carried out using DIG High Prime DNA Labelling and Detection
Starter Kit II (Roche) following the protocol provided by the manufacturer. Briefly, digested
DNA was separated on a 0.7% agarose gel, soaked in 0.25 M HCl for 15 min, and alkaline
transferred onto nylon membranes (Boehringer Mannheim). The membranes were prehybri-
dized in Hybrisol I (Millipore) for 1 h at 42˚C. A DIG-labelled probe was applied for hybrid-
ization, and the hybridized DNA was visualized using the detection kit.
Cesium chloride gradient equilibrium centrifugation
DNA was mixed with cesium chloride (CsCl), and the mixture was adjusted to a volume of 4.5
ml, and a the density of 1.753 g/ml (i.e. corresponding to a refractive index of 1.404). The
DNA-CsCl solution was transferred to Beckman ultracentrifuge tubes, and samples were cen-
trifuged at 30,000 rpm at 22˚C for more than 48 h in a SW55 rotor. After centrifugation, the
tube was inserted into a gradient collector, a hole was punctured at the bottom of the tube, and
fractions of 5 drops each were collected in Eppendorf tubes (up to 50 fractions). The DNA
concentration of each fraction was measured using a spectrophotometer, and the refractive
index measured using a refractometer, after which the fractions were slot blotted onto a posi-
tively charged nylon membrane. The wells of the slot blotter were washed with denaturation
buffer (0.5 M NaOH, 0.5 M NaCl). The membrane was then air dried and UV cross-linked.
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The HPV genomes were detected using DIG-labelled probes (see Southern blot analyses
above).
Results
HPV16, but not HPV11 genomes, are maintained in keratinocytes during
passage in tissue culture
In order to compare the specific requirements for HPV16 and HPV11 genome replication in
‘infected’ basal-like keratinocytes we used NIKS cells, which are an isogenic immortal kerati-
nocyte cell line previously shown to recapitulate the full epidermal differentiation program in
vitro and to support the full HPV life cycle [22–24]. In order to establish NIKS cells harboring
low- and high-risk HPV genomes, HPV11 and HPV16 genomes were transfected into NIKS
cells along with a plasmid encoding a blasticidin resistance gene. Following drug-selection
with blasticidin S, cells containing the HPV genomes were expanded and maintained at sub-
confluent conditions for 2 to 8 passages. Total DNA was extracted at each passage and treated
with DpnI to remove the input genomes, and the levels of replicated viral genome were moni-
tored by qPCR using GAPDH as a reference gene to calculate the HPV genome copy number
per cell. As previously indicated [25–27], the HPV11 genome copy number rapidly declined
upon passage to typically reach less than 0.2 copies/cell by passage 8 (Fig 1A). In contrast,
HPV16 genomes, and indeed the genomes of other high-risk HPV types [23], persisted at a
uniform copy number throughout the experiment. Although the actual HPV genome number
varied between experiments, and was different for each HPV type, the trend was similar
between passages. In order to overcome these tissue culture issues, and to carry out our experi-
ments in a more controlled manner, we decided to monitor the viral genome copy number
variations within the same passage (passage 2), growing cells from sub-confluent to post-con-
fluent conditions in a 7 day time-frame. Previous studies have indicated that epidermal kerati-
nocytes cultured in vitro switch between two interconvertible growth modes depending on the
local cell density: an expanding growth mode, characterized by and excess of proliferating
cells, and a balanced growth mode in which proliferation is counterbalanced by differentiation
[28]. Similarly, as can be seen in Fig 1B (upper panels), NIKS cells grown in monolayer switch
from a proliferative and undifferentiated (expanding) growth mode at sub-confluence (Day 3),
in which they express the cell cycle progression marker MCM7 in the absence of the early kera-
tinocyte differentiation marker keratin 10 (K10), to a differentiated and post-mitotic (bal-
anced) growth mode at post-confluence (Day 7). Interestingly, when low passage NIKS
harboring HPV11 and HPV 16 (passage 2 post-transfection/selection) were analyzed in a simi-
lar way, NIKS/HPV11 showed a very similar growth pattern to that of parental NIKS Fig 1B
middle panels, Fig 1C and 1D), indicating that low-risk HPV fails to modulate keratinocyte
homeostasis. In contrast however, while HPV16 did not significantly affect the growth mode
of NIKS at sub-confluence, it conferred a potent proliferative capacity to post-confluent cells,
which was accompanied by a loss of keratinocyte differentiation marker (Fig 1B lower panels,
Fig 1C and 1D). This indicates that HPV16 is able to overcome the normal contact inhibition
signals promoting the maintenance of an expanding growth mode at high cell densities. We
then went back to analysing the HPV genome copy number in low passage (passage 2)
HPV11/16 transfected NIKS, and found that both HPV11 and HPV16 have the same ability to
maintain their genomes in sub-confluent keratinocytes (Fig 1D; days 1–4). At post-confluence
(Day 7), however, HPV16 genome copy number undergoes an approximately 3-fold increase
relative to day 4, while HPV11 genome copy number declined significantly (Fig 1E). When
taken together, these data indicate that maintenance-replication of both low- and high-risk
HPV types can be similarly efficient, but that HPV11 is unable to overcome keratinocyte
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differentiation at higher cell density, which compromises its replication ability. In all cases,
viral genomes were episomal, as experiments were carried out shortly after transfecting circu-
larized virus genome (confirmed by Southern blotting at passage 2 ([18], S1 Fig)). As predicted
from this, transcript mapping studies revealed a characteristic ‘episomal’ pattern of viral gene
expression in both HPV16 and HPV11-NIKS, with the majority of transcripts spanning E6
and E7, and terminating downstream of the E5 ORF[18].
HPV 11 and HPV16 are replication competent in keratinocytes, with
similar partitioning characteristics
As NIKS cells underwent 2 or 3 doublings during the first 4 days of our experiments, our data
suggest that HPV11 does not differ from HPV16 in its overall replication competence, and can
replicate along with cellular DNA in proliferating keratinocytes. Importantly, our results also
suggest a similar ability of both genomes to partition accurately during cell division. To inves-
tigate this further, a hEF1-HTLV promoter/GFP-Blastocidin reporter cassette was inserted
into the late gene region of HPV11 and HPV16 (Fig 2A) in order to directly visualize cells con-
taining HPV genomes following transfection, an approach similar to the that used previously
[29, 30]. The GFP-Blastocidin fusion gene also allowed the use of drug-selection to enrich for
cells harbouring recombinant viral episomes. This is particularly important for low-risk HPV
types such as HPV11, which does not obviously modify the cell phenotype, and has a tendency
to decline in copy number over passage (Fig 1A and 1B). To examine whether the GFP inten-
sity correlated with HPV copy number, NIKS cell populations harboring either the HPV11 or
HPV16 reporter genomes (i.e. NIKS/HPV11GFPbsr or NIKS/HPV16GFPbsr, respectively),
were separated by fluorescent activated cell sorting (FACS), into 4 groups according to the
intensity of the GFP signal. Total DNA was subsequently extracted from each group, and HPV
genome copy number was quantified by qPCR. In both the NIKS/HPV11GFPbsr and NIKS/
HPV16GFPbsr populations, the intensity of the GFP signal correlated well with HPV genome
copy number (Fig 2B). The NIKS/HPV11GFPbsr and NIKS/HPV16GFPbsr populations were
then seeded along with parental NIKS at a ratio of 1:50. Colonies were allowed to expand in
the dish for 4 days without drug selection, before being fixed and examined by fluorescent
microscopy. Single GFP-positive cells were readily apparent immediately after plating, with
larger GFP-positive colonies developing by day 4. Although there was great diversity in the
GFP signal, suggesting great diversity in viral copy number, in individual colonies, individual
cells within the same colony always showed uniform levels of fluorescence, irrespective of
whether they contained HPV16 or HPV11 genomes (Fig 2C and 2D). In fact, when normalized
to the mean GFP intensity of each colony, the variation in GFP intensity amongst individual
cells in both NIKS/HPV11GFPbsr and NIKS/HPV16GFPbsr colonies was broadly similar (Fig
2E). When taken together, these results suggest that the HPV11 genome is partitioned with
similar dynamics to that of HPV16 in proliferating keratinocytes.
Increased cell density mediates a switch from E1-independent to
E1-dependent replication
Following papillomavirus infection of basal keratinocytes, the productive phase of the virus life
cycle is triggered by host keratinocyte differentiation, with viral genome replication and ampli-
fication rising gradually as cells enter the suprabasal layers, followed eventually by the expres-
sion of viral capsid proteins and virion assembly in the uppermost layers of the epithelium [31,
32]. The fact that HPV11 is unable to maintain or amplify its genome during the commitment
to differentiation in our experimental setting (Fig 1B and 1E), indicates that the modulation of
keratinocyte differentiation is crucial for genome maintenance, and that differentiation-
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commitment can negatively influence the HPV replication machinery. During productive
infection, the viral DNA helicase E1 is essential for genome amplification in the mid epithelial
layers [7], whereas the importance of E1 for maintenance-replication in basal keratinocytes is
still controversial [17, 33]. This data suggests that HPV might follow a ‘two-phase’ replication
mode with respect to E1-dependency [34]. To establish the contribution of E1 to HPV16/11
maintenance-replication, as well as for HPV16 genome amplification in differentiating kerati-
nocytes, E1 deficient mutants were generated in the context of the full length HPV11 and
HPV16 genomes (HPV16E1def & HPV11E1def), and stable NIKS populations were estab-
lished as described above. At the time of seeding for the experiment, (passage 2 post-transfec-
tion/selection) viral genomes were predominantly episomal as determined by Southern
blotting (S1 Fig). The viral genome copy number was monitored to see its variations within
the same passage in the same way as shown in Fig 1E). As can be seen in Fig 3A, both
HPV11E1def and HPV16E1def genomes were maintained at similar levels as the WT genomes
until day 4 during the ‘maintenance-replication’ phase, but declined dramatically post-conflu-
ence (Day 7). These data support the hypothesis that HPV16 at least, can switch its replication
mode from E1-independent to E1-dependent replication as cell density increases, and that
HPV16 does not simply hamper transit to a balanced growth mode at high cell density and
prolong the expanding growth mode as well as the maintenance replication of virus genome.
In addition, these results show that both HPV11 and HPV16 can replicate without the E1 viral
helicase in expanding NIKS cells, and that the inability of low-risk HPV to overcome differen-
tiation signals triggered by high cell densities has dramatic consequences on their replication
capacities. To support these conclusions, a second set of E1 defective mutants were made in
the context of the HPV16 and 11 genomes, this time to disrupt the integrity of the conserved
E1 helicase domain that is essential for E1’s replicative function (HPV11 E1K484A and HPV16
E1K483A)[35]. The results obtained with these mutants were indistinguishable from those seen
with HPV11E1def and HPV16E1def mutants (Fig 3B).
Fig 3. Requirement of a helicase-active E1 for genome amplification but not maintenance. (A) The virus genome
copy number per cell of E1-defective HPV11 (HPV11E1def, upper) and HPV16 (HPV16E1def, lower) transfected
NIKS was measured, and prepared for presentation as outlined in Fig 1E. (B) The virus genome copy number per cell
of E1 helicase-defective HPV11 (HPV11E1K484A left) or HPV16 (HPV16E1K483A, right) transfected into NIKS was
measured and prepared for presentation as outlined in Fig 1E. Both the HPV11 E1K484A and HPV16 E1K483A genome
declined post-confluence in the absence of a helicase-active E1 gene.
https://doi.org/10.1371/journal.ppat.1007755.g003
Low-risk HPV E6 degrades p53 to conduct E1-dependent replication
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007755 May 13, 2019 11 / 28
To determine the two modes of HPV DNA replication in different cell density, we investi-
gated how many times HPV DNAs replicate in a single S phase by labelling cells with BrdU
[26, 27, 34]. As Hoffman et al. reported, DNAs that have replicated once will incorporate BrdU
on a single DNA strand (heavy-light, HL). Those that have replicated more than once will
incorporate BrdU on both strands (heavy-heavy, HH), and those that didn’t replicate will have
no BrdU in their DNA (light-ligh, LL). These three DNA species were separated on a cesium
chloride gradient according to their different densities, with LL DNA at 1.709 g/ml (Refractive
Index (RI) = 1.400), and HL DNA at 1.753 g/ml (RI = 1.404) and HH DNA at 1.795 g/ml
(RI = 1.708) (Fig 4A and 4B). Both HPV16WT and HPV11WT genomes were replicated once
Fig 4. Synchronous HPV DNA replication durind sub-confluent growth. (A) Profile of NIKS cellular DNA 18 h after BrdU labelling. The DNAs were
separated on a CsCl gradient, and fractions were collected. In each fraction, refractive index (RI) and DNA concentration were measured by a
spectrophotometer and a refractometer respectively. The positions of heavy-heavy DNA (HH), heavy-light DNA (HL), and light-light DNA (LL) are
marked. (B) DNA of NIKS containing HPV16 or 11 was collected at day 3 and 7 of passage 2 following 18 h of BrdU labelling. The DNAs were separated
on a CsCl gradient, and fractions were collected as before. Fractions where the RI indicated the possible presence of DNA (HH, HL or LL) were blotted,
before the detection and quantitation of HPV DNA using DIG-labelled probes. (C) DNA from NIKS containing HPV16 or 11 genomes was collected at
3 days post-transfection following 18 h of BrdU labelling. HH, HL or LL HPV DNA was separated and detected as described in (B).
https://doi.org/10.1371/journal.ppat.1007755.g004
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in a single S-phase, with the emergence of HL viral DNA, but not HH viral DNA at day 3 dur-
ing the E1-independent maintenance replication phase (Fig 4B). In contrast, the HPV16 WT
genome was replicated more than once at day 7, during the E1-dependent replication phase,
with the emergence of HH viral DNA at day 7 (Fig 4B). These results suggest that the mode of
HPV genome replication switches from a synchronous mode (i.e. once in a single S-phase), to
amplification mode (i.e. multiple times in a single S-phase) in a cell-density related manner.
During the establishment of infection, it is thought that one single viral particle may efficiently
establish the full viral intracellular life cycle [36], suggesting that the papillomavirus DNA copy
number is amplified to a certain level (50 to 400) per cell immediately after infection. Prior to
P1, at 3 days post transfection, both HPV16WT and HPV11WT genomes were replicated once
in a single S-phase, with the emergence of HL viral DNA but not HH, with only a small pro-
portion of total HPV DNA contributing to replication (Fig 4C). At this point the majority of
the viral DNA extracted from the NIKS cells is DpnI sensitive (91.2% (1.6 standard deviation)).
Interestingly, both the HPV11 and 16 E2 defective genomes were not successfully replicated,
with no HL and HH viral DNA produced (Fig 4C). These results suggest that in our experi-
ments during the establishment phase, HPV genomes are replicated once per S-phase in an
E2-dependent manner, after the introduction of multiple copies of viral DNA by transfection.
We suspect that the initial amplification phase that occurs after infection by a single virus, and
which is thought to be E1-depenent, is bypassed as a result of the introduction of a high copy
number of episomal viral DNA by transfection.
HPV11 genome is replicated post-confluence in the presence of HPV16 E6
and E7
Although E1 is dispensable for the maintenance of either HPV11 or 16 genomes in dividing
NIKS cells, it is clearly important for the HPV16 genome copy number elevation in post-con-
fluent keratinocytes, with E1 disruption leading to HPV16 genome loss as cells transition to
post-confluence. The different abilities of HPV11 and HPV16 to replicate their genomes in
keratinocytes at high cell density prompted us to investigate the interplay between the viral
replicative machinery and the HPV accessory proteins E6 and E7. Recent studies indicate that
HPV16 E6 has a predominant role, over E7, in skewing basal keratinocyte cell fate towards
proliferation by inhibiting differentiation in a p53- and Notch-dependent manner [20, 37]. In
order to assess the potential roles of E6 and E7 functions in creating a replication-competent
environment for the virus, we tested whether high-risk HPV E6/E7 proteins might comple-
ment the replicative deficiency of HPV11 at high cell densities. To do this, we established
NIKS cells stably expressing HPV16 E6 and/or E7 by retroviral transduction, and the expres-
sion of E6 and E7 were confirmed by western blot analysis (S2A Fig). The HPV11 genome was
transfected into these cell lines and NIKS transduced with empty vector (LXSN) as a control,
and, following drug selection, cells were seeded at passage 2 or 3 post-transfection for the eval-
uation of the viral genome copy number. Strikingly, the expression of HPV16 E6 and/or E7
allowed replication of the wild-type HPV11 genome post-confluence (Fig 5A left panel), which
was associated with an inhibition of differentiation and p53 expression when HPV16 E6 was
expressed either alone or in combination with E7, as well as a potent increase in the cell-cycle
activity post-confluence (Fig 5B and 5C). It is interesting to note however, that unlike E6,
HPV16 E7 exerts its function by uncoupling cell-cycle entry from differentiation as previously
reported [38]. In order to confirm that the expression of the viral helicase E1 was indeed neces-
sary to mediate post-confluence HPV11 genome maintenance in the presence of HPV16 E6
and E7, we transfected the E1-defective HPV11 genome in NIKS expressing HPV16 E6 and/or
E7 and the viral genome copy number was monitored across 7 days. The results of this assay
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Fig 5. Low-risk HPV is maintained in NIKS expressing high-risk HPV E6 and E7 post-confluence. (A) The virus genome copy number per cell of
HPV11 (left) and HPV11 E1def (right) transfected into NIKS or NIKS expressing HPV16 E6 and/or E7, was measured and prepared for presentation as
outlined in Fig 1E. (B) NIKS or NIKS expressing HPV16 E6 and/or E7 at days 3 and 7 were stained with K10 (red); MCM (red), p53 (red), and DAPI
(blue). Bar = 200μm. (C) The proportion of MCM positive cells shown in (B) is quantified and shown.
https://doi.org/10.1371/journal.ppat.1007755.g005
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are shown in Fig 5A (right panel), and as can be seen, the lack of a functional E1 gene product
impaired the ability of HPV16 accessory proteins to rescue HPV11 genome replication post-
confluence. Taken together, these data indicate that there is an interplay between the replica-
tion and accessory proteins of HPV, and that disruption of this interplay affects genome main-
tenance as cells transit towards a balanced growth mode and E1-dependent replication is
triggered at high cell density. Our data suggest that maintenance replication in dividing basal
cells prior to this may be E1-independent.
The inactivation of p53 is required for viral genome replication post-
confluence in both HPV11 and HPV16, but not for maintenance
replication in sub-confluent cells
Previous studies indicate that the ability of HPV16 E6 to target p53 and PDZ domain-contain-
ing proteins for degradation is required for the successful completion of the viral life cycle [16,
39–41]. Our result showing that 16E6 is able to facilitate HPV11 replication post-confluence,
prompted us to investigate what functions of the 16E6 protein are essential to mediate this
effect. To do this, we established two NIKS cell lines by retroviral transduction, to express
either the HPV16 E6 SAT mutant (NIKS/LXSN-16E6SAT), which is unable to bind and target
p53 for degradation, or the PDZ-binding defective mutant (NIKS/LXSN-16E6ΔPBM), which
lacks the C-terminal PDZ-binding motif (PMB) responsible for the association with PDZ pro-
teins. The wild-type HPV11 genome was transfected into these cell lines, and genome replica-
tion was assessed in sub- and post-confluent cells. As expected, neither of the 16E6 mutants
affected HPV11 genome maintenance sub-confluence (Fig 6A), with the loss of p53-degreda-
tion capability alone, affecting E6’s ability to support viral genome replication post-confluence
(Fig 6A). In order to further examine the importance of p53-loss on genome maintenance as
cells become confluent, the expression of p53 was transiently ablated by RNA interference
(siRNA) in NIKS cells harboring wild-type HPV11 genomes, and the effects on genome main-
tenance and replication are shown in Fig 6B. As can be seen, the levels of p53 were efficiently
reduced both in sub- and post-confluent cells (Fig 6B lower panel), and consistent with this, a
higher level of maintenance replication was seen in sub-confluent cells from days 2 to 4 (Fig
6B upper panel). Intriguingly, the ablation of p53 had its most dramatic effects post-conflu-
ence, where cells transfected with the control non-targeting (NT) siRNA showed the most dra-
matic decline in HPV11 copy number (Fig 6B upper panel). These results suggest that p53
binding, but not the association with PDZ domain-containing proteins, is necessary and suffi-
cient to allow HPV genome maintenance in confluent keratinocytes. In order to confirm that
a similar role for E6 during HPV16 replication, we engineered the wild-type HPV16 genome
to express either an E6 protein defective in its PDZ-binding activity (E6ΔPBM), or the E6SAT
mutant that is unable to interact and degrade p53. Mutant genomes were transfected into
NIKS, and after selection, low passage NIKS transfectants were seeded and viral genome repli-
cation assessed. As can be seen in Fig 4C, both HPV16E6ΔPBM and HPV16E6SAT mutant
genomes were replicated until day 4, but the copy number of HPV16E6SAT mutant genome
dramatically declined post confluence at day 7 (Fig 6C, right). In contrast, the HPV16E6ΔPDZ
mutant genome was amplified as efficiently as the wild-type genome (Fig 6C, left). These
results suggest that E6-mediated p53 inactivation contributes to genome maintenance as cells
reach confluence, and point perhaps to a more important role in this than for E7.
Previous studies have shown E6 and E7, but not E4 and E5, to be required for the establish-
ment and maintenance of HPV genomes in keratinocytes in a tissue culture model [18, 25, 42–
44]. Our results suggest that E1, and some of 16E6 functions (degradation of p53 and PDZ-
proteins) are not required for replication in growing keratinocytes. To address this further, E6
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and E7 deficient mutants in the context of HPV11/16 genomes, were transfected into these cell
lines, and the viral genome copy number monitored over 7 days. As can be seen in S3A and
S3B Fig, both E6 and E7 defective genomes of HPV11 and 16 were established and maintained
at levels similar to those of the WT genomes until day 4 during the ‘maintenance-replication’
phase, but declined dramatically post-confluence (Day 7). This data supports the idea that E6
and E7, the viral accessory genes, are required only for E1-dependent replication but not for
E1-independent replication.
Although most of the HPV11 and HPV16 mutant genomes replicated successfully in sub-
confluent NIKS cells (with the exception of the E2 knock out), we have not been able to estab-
lish long term cultures of NIKS cell lines harboring any of these HPV genomes, which is con-
sistent with our earlier studies on cell passage, as well as with previous reports [16, 40]. As
HPV16SAT and HPV16E1def genome copy numbers also declined during passage, we con-
clude that E1 and the inhibition of p53 are required for long-term tissue culture maintenance
of HPV16 genomes (S4A Fig). Interestingly, the ability of 16E6 to target PDZ proteins, as well
as the presence of E7, was also required for the genome maintenance during cell passage in
this system (S4A Fig) [16]. Previous reports suggest that the stress induced by cell passaging
triggers keratinocyte differentiation via activation of the Notch pathway [45], indicating an
Fig 6. Inactivation of p53 rescues genome maintenance of low-risk HPV post-confluence. (A) The virus genome copy number per cell of HPV11
transfected NIKS or NIKS expressing 16E6, HPV16 E6ΔPBM (16E6ΔPBM) or HPV16 E6SAT (16E6SAT) was measured and prepared for presentation as
outlined in Fig 1E. (B) The viral genome copy number per cell of HPV11 in NIKS transfected with siRNA (control (NT) or to p53) was carried out as in Fig
1E. Cells were collected at day 3 and 7 to establish p53 levels in the different cell populations (right). (C) The full genome of HPV16E6ΔPBM (left) or
HPV16E6SAT (right) was transfected into NIKS. The viral genome copy number per cell was measured and prepared for presentation as outlined in Fig
1E.
https://doi.org/10.1371/journal.ppat.1007755.g006
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overlapping mechanism of viral genome loss during passaging and at high cell densities, where
E1-dependent replication could be triggered by the induction of keratinocyte differentiation.
The fact that HPV11 WT genomes were not maintained over passage also in the presence of
HPV16E6 and E7 (S4B Fig), suggests that the requirements for copy number maintenance
during passage are more stringent than those that affect cells at and around the point of conflu-
ence. Our focus here is on the latter, given that this is the more physiologically relevant
situation.
HPV11 E6 is able to stimulate p53 degradation in a cell density-dependent
manner and support the replication of HPV11 post-confluence
Previous studies have shown that HPV11 can inhibit p53 transactivation activity in an E6AP-
independent manner through association with the p300 acetyl-transferase/transcriptional co-
activator [46, 47], but have not yet revealed a p53 degradation capability comparable to that of
HPV16. To understand HPV maintenance regulation further, viral transcripts from NIKS/
HPV11 and NIKS/HPV16 cells grown to sub-confluence (Day 3) or post-confluence (Day 7),
were examined following cDNA synthesis and qPCR. Interestingly, the level of the early pro-
moter activity of HPV11 (p90) was very low when compared with HPV16 (p97) especially at
day 7 (typically around 200 and 10500 copies per 1000 GAPDH mRNA copies respectively
across repeat experiments). The expression level of transgenes from LXSN retrovirus vector is
between 6000 and 12000 copies per 1000 GAPDH, which is broadly equivalent to the tran-
scriptional activity of HPV16 early promoter. This result suggests that NIKS cells grown in
monolayer may not support the expression of HPV11 E6 and E7 at levels high enough to allow
viral genome replication post-confluence. To evaluate whether HPV11 E6 and E7 could have a
similar effect to their HPV16 counterparts in mediating the replication of HPV11 genome
post-confluence, we established NIKS cells stably expressing HPV11 E6 (NIKS/LXSN-11E6)
and/or HPV11 E7 (NIKS/LXSN-11E6E7 and NIKS/LXSN-11E7) by retroviral transduction.
After confirming the expression of HPV11 E6 and E7 in these cell lines by RT-PCR (S2B Fig),
control (LXSN) and HPV11 E6 and/or E7-expressing NIKS were further transfected with the
HPV11 genome, and the levels of viral replication were assessed by qPCR as described above.
The HPV11 genome was again well maintained until day 4 in control NIKS, as well as in the
presence of 11E6 and/or 11E7 during this ‘maintenance replication’ phase (Fig 7A left panel).
As seen with HPV16 E6 and E7 however, the HPV 11 E6 and E7 proteins could also facilitate
the replication, albeit not the amplification, of the HPV11 genome post-confluence. Further-
more, the lack of a functional HPV11 E1 gene impaired this post confluence maintenance abil-
ity, which appears to be mediated by a switch to E1-dependent replication (Fig 7A left panel).
These results suggest that HPV11 E6 and E7 are similar to the HPV16 proteins in supporting
HPV11 genome replication in post-confluence cells providing that they are present at suffi-
ciently high levels. Having shown that HPV11 E6 and E7 are functionally equivalent to the
high-risk HPV accessory proteins in supporting viral genome maintenance, we were interested
in understanding how HPV11 E6 and E7 may achieve this. To do this, freshly transfected low
passage control NIKS/LXSN harboring HPV11 genomes, and NIKS/HPV11 expressing
HPV11 E6 and/or E7 were seeded, and the levels of MCM7, p53 and keratin 10 were assessed
by immunofluorescence at sub- and post-confluence, similar to the experiments carried out
using the HPV16 E6 and E7 proteins earlier (Fig 5). As shown in Fig 7B and 7C, and consistent
with previous reports [48], at sub-confluence HPV11 E6 and E7 failed to significantly increase
the levels of cell-cycle entry of NIKS or to promote the degradation p53. Surprisingly however,
in post-confluent cells, HPV11 E6 and E7 showed very similar effects to those seen earlier with
HPV16 E6 and E7 (Fig 7B and Fig 5); with HPV11 E6 leading to a loss of p53, an increase in
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Fig 7. Low-risk HPV is maintained in NIKS expressing low-risk HPV E6 and E7 post-confluence. (A) The virus genome copy number per cell of HPV11
(left) and HPV11 E1def (right) transfected into NIKS or NIKS expressing HPV11 E6 and/or E7 was measured and prepared for presentation as outlined in
Fig 1E. (B) The NIKS and NIKS expressing HPV11 E6 and/or E7 at day 3 and 7 were stained with K10 (red), MCM (red), p53 (red) and DAPI (blue).
Bar = 200μm. The images of NIKS at day 3 and 7 were shown previously in Fig 3C. (C) The proportion of MCM positive cells shown in (B) is quantified and
shown.
https://doi.org/10.1371/journal.ppat.1007755.g007
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the number of cycling cells, and an inhibition of commitment to differentiation at high cell
densities. As mentioned previously, the level of the early promoter activity of HPV11 (p90)
was not sufficient to show these phenotypes in this experimental model (Figs 5 and 7B and S5
Fig). Like HPV16 E7, HPV11 E7 was found to uncouple differentiation from proliferation (Fig
7B and 7C). To our knowledge, this is the first demonstration that both HPV11 and HPV16 E6
can similarly reduce p53 levels in the cell, albeit for 11E6, in a cell density-dependent manner.
As a result of this, we were interested to establish whether the HPV11 E6-mediated loss of p53
in post-confluent cells occurs through a mechanism similar to that used by HPV16 E6. First
we confirmed the immunofluorescence data by monitoring the levels of p53 in the presence of
HPV11 E6 and/or E7 at sub- and post-confluence by Western blotting analysis, using HPV16
E6 as a positive control. As can be seen in Fig 8A, the expression of HPV16 E6 in NIKS cells
led to a potent degradation of p53 at both time points, which also resulted in an inhibition of
expression of the p53 target gene p21. Conversely, HPV11 E6, when expressed either alone or
Fig 8. HPV11 E6 drives a reduction in p53 levels only at post-confluence. (A) Whole cell extracts of NIKS or NIKS expressing 16E6, 11E6, 11E6/
E7 and 11E7 at day 3 and 7 were used to assess the levels of p53 and p21 by western blot. (B) A p53 reporter assay was performed to assess p53
transcriptional activity. Each assay was carried out either at day 3 and 7 using NIKS or NIKS expressing 16E6, 11E6, 11E6E7 and 11E7. The activity
of firefly luciferase normalized using the activity of Renilla luciferase. The p53 transcriptional activity of NIKS at day 3 was set at 100%, and other
measurements normalised to this. (C) 1nM of the proteasome inhibitor, MG-132, or an equal volume of the carrier (dimethyl sulfoxide) was added
to NIKS or NIKS expressing 11E6 or 11E6E7, and incubated for 3 hrs. Whole cell extracts were used to assess the level of p53 by western blotting.
The loss of p53 protein was restored by proteasome inhibition. (D) Elevation in growth rate in NIKS expressing 11E6, in comparison with the
parental NIKD-LXSN cells. 11E6 has similar effects on cell growth, particularly post-confluence.
https://doi.org/10.1371/journal.ppat.1007755.g008
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in combination with HPV11 E7, led to a reduction of p53 and p21 levels, but in this case, p53
loss was restricted to the post-confluent cell populations. As expected, HPV11 E7 had no influ-
ence on p53 levels in the rich culture medium conditions used at either day 3 or 7. The cell
density-dependent inhibition of p53 transcriptional activity that is suggested from the p21
western blots described above, was further confirmed using a reporter gene assay, in which
luciferase was expressed from a plasmid-containing tandem repeats of p53 responsive DNA
elements (Fig 8B). In support of this, HPV11 E6 strongly affected p53 transcriptional activity
only at high cell densities, whereas HPV16 E6 did so irrespective of the cell confluence status.
Since HPV16 degrades p53 in an E6AP- and proteasome-dependent manner [49], we tested
whether HPV11 E6 could also use this mechanism of p53 degradation in post-confluent cells.
To do this, control (LXSN) NIKS cells or NIKS expressing HPV11 E6 alone or in combination
with E7 were grown post-confluence and treated with the proteasome inhibitor MG-132 for
an additional 3 hours prior cells were harvested and the levels of p53 monitored by Western
blotting analysis. As can be seen in Fig 8C, our proteasome inhibition had no effect on p53 lev-
els in control cells. In post-confluent NIKS expressing HPV11 E6 and E6/E7 the levels of p53
were strongly reduced however, with proteasomal inhibition leading to a potent up-regulation
of the p53. Interestingly the 11E6 mutant (W133R), which cannot bind to E6AP [25, 50], still
reduced p53 level at post-confluence (S6 Fig), suggesting that 11E6 mediates p53 degradation
in an E6AP-independent manner. This conclusion is supported by a complimentary experi-
ment showing that 11E6 is also able to reduce p53 abundance in the presence of shRNA against
E6AP at post-confluence (S6 Fig). As expected from these results, HPV11 E6 conferred a
potent proliferative capacity, especially on post-confluent cells, which was similar to what was
seen with HPV16 E6 (Fig 8D). From this we conclude that HPV11 E6 is able to exploit the pro-
teasomal pathway in order to target p53 for degradation, and suggest that this is regulated in
the epithelial basal layer to support virus genome maintenance in response to increasing cell
density and the eventual need to differentiate and enter the virus productive cycle.
Discussion
The study of papillomaviruses has for the most part, focused on the association of high-risk
Alpha papillomavirus types with anogenital and oropharyngeal cancers, and as a result of this,
our knowledge of these types is more complete than our understanding of the low-risk Alpha
papillomaviruses. The functional differences between low- and high-risk gene products, espe-
cially those encoded by the E6 and E7 accessory genes, provides a molecular explanation for
the cancer-causing properties of the high-risk HPV types (see [6, 11, 39]). The low-risk types
have however been as evolutionarily successful as the high-risk HPVs, and with respect to the
molecular evolution of alpha HPVs and niche adaptation, their life cycle strategies centre
around a basic set of molecular functions that are required by all alpha HPVs to complete their
productive life cycle, with high-risk types having evolved additional functions which confer
their oncogenic properties. The similarities, as well as differences between high- and low-risk
papillomaviruses, particularly in the context of the virus life cycle, have not yet been elucidated
in any detail. In this study, we have compared the replication capabilities of the two most rep-
resentative members of the high-risk (HPV16) and low-risk (HPV11) alpha papillomavirus
groups in a common keratinocyte background, and have analyzed the fluctuation in genome
copy number over sequential passage, as well as day by day within a single passage. In contrast
to HPV16, HPV11 was poorly maintained over passage, which is in agreement with previous
reports [25, 51]. To our surprise however, both the HPV16 and HPV11 genomes replicated
similarly in proliferating sub-confluent keratinocytes within the same passage, with the ten-
dency towards keratinocyte differentiation as cell density increases, representing a crucial
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regulatory point that HPVs must control if their genomes are to be maintained long term. This
modulation reflects a requirement for HPVs to subtly disturb normal epithelial homeostasis to
favour retention of the infected cell in the basal layer [20]. At the point where keratinocytes
transit to the balanced growth mode as cell density increases, the HPV replication mode
appeared to switch from being an E1-independent/E2-dependent synchronised mode to an
E1-dependent unsynchronised mode. At the same time, keratinocyte differentiation was sup-
pressed by E6, with cell cycle re-entry (for genome amplification) being mediated by E6 and
E7 (Figs 3C and 5B). In contrast to HPV16, where viral gene expression and the phenotypic
consequences for the cell can be understood, for HPV11 only low levels of viral gene expres-
sion were apparent, which may cause low level modulation of p53 level (Fig 6B, right panel),
but was not sufficient to show inhibition of differentiation and promotion of cell cycle at post-
confluence (Figs 5B and 7B). When the HPV11 E6 and E7 proteins were expressed exoge-
nously from a retroviral vector however, they had very similar effects on the cell as seen with
16 E6 and E7, with E6 promoting the proteasome-mediated degradation of p53 and inhibiting
keratinocyte differentiation, which is thought to take place in the basal and/or parabasal layers,
and E7 uncoupling cell-cycle entry from differentiation, which is thought to take place in the
parabasal and upper layers. Of some importance however, was our observation that the
HPV11 E6 protein was able to promote the degradation of p53 in a cell density-dependent
manner via E6AP independent manner, which suggests that the mechanism of p53 regulation
by low-risk HPV types is more subtle than that of the high-risk types. It is interesting to note
however, that in both HPV11 and HPV16, E1 function as well as p53 inhibition were dispens-
able for viral genome replication up until the point that cells were triggered towards differenti-
ation at confluence. These two phases in the virus replication cycle are intimately linked to the
biology of the differentiating keratinocytes infected by the virus. The expanding and the bal-
anced growth modes observed in keratinocytes grown in monolayer have been shown to
broadly recapitulate the growth dynamics in epithelial tissues in vivo [28]. During the expand-
ing growth mode in sub-confluent cells, which is suggestive of a wound-healing environment
in the epithelium [28, 52], both HPV16 and HPV11 genomes are replicated and maintained in
a E6/E7- and E1-independent manner. In contrast, when a balanced growth mode was trig-
gered, which resembles the differentiation dynamics regulating stratified epithelial homeosta-
sis [28, 53]), the HPV replication mode switched towards E1-dependency and required the
functions of the accessory genes, E6 and E7. It is reasonable to speculate that a balanced growth
mode is followed in at least a proportion of basal keratinocytes, since the commitment to dif-
ferentiation has been shown to occur already in the basal layer [20, 54]. This suggests that an
E1-independent replication mode might be used by HPVs to promote the long-term genome
maintenance in the basal layer of the epithelium during productive infection, as well during
subclinical or latent infections that may be subject to immune control. These are important
considerations when evaluating possible targets for therapy, with E1 inhibitors having a role
primarily as viral genome amplification occurs during epithelial differentiation, rather than
ubiquitously at all stages of the virus life cycle. Interestingly, a well-studied two-phase replica-
tion strategy is also used by Epstein-Barr virus (EBV) during its latent and lytic phases. In this
case, the EBV genome is replicated once per S phase in the latent phase of infection [55, 56],
and at this point EBV expresses only a few viral genes and employs the host-encoded replica-
tion licensing proteins, MCMs and ORC, for replication, a process which is facilitated by the
viral protein EBNA-1 [57]. Interestingly HPV E2 and EBNA-1 shares structural and functional
similarities, even though the sequence are not conserved [58–61]. Recently, the interaction
between HPV31 E2 and ORC2 has been reported, although its contribution to viral genome
replication is unclear [62]. Our data indicate that HPV may also have a latent replication
phase, in which the viral genome is replicated once per S phase mediated by E2 (Fig 4). It is
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currently unknown whether and how MCMs and ORCs are involved in HPV DNA replica-
tion, but we speculate that the E1-independent/E2-dependent maintenance replication
employs the cellular replication machinery to support viral genome maintenance under S
phase control. In addition, E1- and E2-independent cis-replicating elements may also reside
outside the LCR and possibly in the late region (L2-L1 open reading frames [ORFs]) of the
HPV16 genome [63].
Our studies also suggest functional similarities in the way that the HPV E6 and E7 proteins
contribute to the phenotype of the infected basal cell, by modifying the cellular environment
to facilitate genome replication. E6 and E7 impact on a range of biological events, including
cell survival, transcription/translation, host cell differentiation, growth factor dependence,
DNA damage responses, and cell cycle progression [11, 12]. In this study, we directly com-
pared the early stages of the high- and low-risk HPV life cycles in a common keratinocyte
background. It is clear from this that E6 plays a critical role in early differentiating keratino-
cytes, as the HPV16 E6SAT mutant genome, which has intact E7 but is incompetent for p53
degradation, failed to support E1-dependent replication in differentiating cells. E7 undoubta-
bly has an important role during the later stages of differentiation, although this was not mod-
elled as part of this study. Our data also link HPV genome replication to the inhibition of
Notch signalling [20]. The E6 proteins of both high and low-risk alpha papillomaviruses have
evolved to stimulate the degradation of p53 (Fig 6A), albeit with different mechanisms (espe-
cially in E6AP-dependency), dynamics and effects expected on Notch signalling (see also [20,
37]). Interestingly, E6 proteins expressed by cutaneous papillomaviruses belonging to the Beta,
Delta and Mu genera associate with MAML1, a Notch transcriptional co-activator, in order to
repress Notch signal transduction [64–66]. Indeed, we suspect that use of these different regu-
latory pathways may reflect the different roles of p53 in regulating differentiation according to
epithelial sites, and the adaptation of HPVs to different epithelial niches where the role of p53
is more or less important. In fact, p53 levels in the basal and parabasal layers of normal ectocer-
vical epithelium are high when compared to normal dermal epithelium [20], which suggests
that this epithelial site is in fact normally regulated by p53, and that p53 may have a fundamen-
tal role in normal homeostatic control at this site [20]. E6 is also expected to play a role in
countering p53-dependent growth arrest and/or apoptosis of course, especially during
E1-dependent genome amplification, where DNA damage sensors ATR or ATM DDR [67, 68]
are triggered. When taken together, our data suggest that HPV 11 and HPV 16, which are both
Alphapapillomavirus, but which are categorized as low or high risk, make use of similar strate-
gies for viral gene replication. During maintenance replication, which occurs in cycling cells in
the absence of differentiation signals, the requirement for viral factors appears minimal, with
E1-independent/E2-dependent replication occurring in the absence of a requirement for
E6-mediated p53 degradation. Once cells reach confluence, they commit to differentiation as a
result of cellular contact inhibition. In this environment, the HPV E6/E7 accessory genes mod-
ulate the cellular environment to facilitate E1-dependent replication by inhibiting differentia-
tion as a result of E6-mediated p53 degradation, which is a characteristic of both the high and
low-risk Alpha HPV E6 proteins. A clear role for E7 in driving cell cycle re-entry for produc-
tive genome replication is apparent across different HPV types. A role in evasion of the innate
immune response and in regulating virus tropism are other important functions that we expect
to be mediated primarily by E6 and E7.
Supporting information
S1 Fig. Validation of the episomal status of HPV genomes in NIKS. Representative South-
ern blot showing the presence of viral episomes in the NIKS cell lines. In the example shown, a
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HPV11 genomic probe was used to detect the HPV11WT and the HPV E1-defective genomes
in NIKS and NIKS cells expressing 16E6 and/or E7, (left), and 11E6 and/or E7 (right). Tracks
contain DpnI / XhoI-digested total DNA isolated from cells collected at passage 1, 8 days after
transfection. DpnI and XhoI do not digest HPV11 genome replicated in NIKS. The BamHI-lin-
earized HPV11 genome was used as copy number control (far left). OC = open circular,
Ln = linear, SC = super coiled.
(TIF)
S2 Fig. Expression of HPV16 and HPV11 E6 and E7 in NIKS cells. (A) NIKS or NIKS
expressing 16E6 and/or 16E7 were cultured to confluence. Cell pellets were lysed using RIPA
buffer, and the viral proteins detected by western blotting as described previously [24]. (B) For
HPV11, E6 and E7 expression was confirmed at the RNA level following cDNA synthesis,
PCR and gel electrophoresis. A reverse transcriptase (RT) negative control (no RT enzyme)
was included in each case.
(TIF)
S3 Fig. Requirement of E6 and E7 for genome amplification but not maintenance. (A) The
virus genome copy number per cell of E6-defective HPV11 (HPV11E6def left) or HPV16
(HPV16E6def, right) transfected into NIKS was measured and prepared for presentation as
outlined in Fig 1E. (B) The virus genome copy number per cell of E7-defective HPV11
(HPV11E7def left) or HPV16 (HPV16E7def, right) transfected into NIKS was measured and
prepared for presentation as outlined in Fig 1E. Both the HPV11/16 E6def and HPV16 E7def
genome declined post-confluence in the absence of a helicase-active E1 gene.
(TIF)
S4 Fig. Change in HPV copy number per cell following passage. (A) The full genome of
HPV16 WT, E1def, E6ΔPBM, HPV16E6SAT E6def or E7def was transfected into NIKS. The
viral genome copy number per cell before passage (Passage 1 and 2) was set at 100%, and each
relative genome copy number per cell 24 hours after passage (Passage 2 and 3) is shown. For
the HPV16 genomes, only the WT genome was maintained at equivalent levels following pas-
sage of cells in tissue culture. Loss of E1 or E6 functions compromised genome maintenance
when cells were subject to passage stress. (B) The virus genome copy number per cell of
HPV11 transfected NIKS or NIKS expressing 16E6, 16E6E7 or 16E7 was measured as outlined
in Fig 1E. The viral genome copy number per cell before passage was set at 100%, and each rel-
ative genome copy number per cell 24 hours after passage (Passage 2 and 3) was shown. The
WT HPV11 genome, which declines following passage, is not rescued following expression of
HPV16 E6 and/or E7, even though these genes prevent copy number loss in confluent cells.
(TIF)
S5 Fig. Expression of p53 in the parental NIKS cell line. NIKS cells at days 3 and 7 were
stained with p53, and with DAPI (blue) as a nuclear counterstain.
(TIF)
S6 Fig. HPV11 E6 drives a reduction in p53 levels by E6AP independent manner. (A) NIKS
or NIKS expressing HPV16 E6, 11E6WT, 11E6W133R, which cannot bind to E6AP are shown
at the day 7 time point (post-confluence) following staining for p53 (red) and DAPI (blue). (B)
NIKS expressing 11E6WT and shRNA targeted against E6AP were stained at day 7 for p53
and DAPI (upper image). The reduction of E6AP level in cells expressing the E6AP shRNA
was confirmed by western blotting (lower image). (C) The proportion of P53 positive cells
shown in (A) and (B) are quantified and shown as a bar chart.
(TIF)
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